PALI Stock — Palisade Bio Inc

Palisade Bio Inc (PALI)

Updated October 16, 2026.

PALI is a Stock. Its deepest 1-year drawdown was 51.8%.

Palisade Bio is a clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 inhibitor prodrugs targeted for delivery to the terminal ileum and colon, with its lead candidate, PALI-2108, currently in phase 1b trials for inflammatory bowel disease including ulcerative colitis and Fibrostenotic Crohn's disease. The company does not currently distribute to shareholders. Palisade Bio may appeal to investors seeking exposure to early-stage drug development with a focus on gastrointestinal disease treatments, though clinical-stage biotech carries substantial development risk.

PALI performance

Returns are updating. PALI's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 51.8%.

PALI key facts

Asset type

Stock

Asset class

Equity

Inception date

12/20/2006

Distribution frequency

None

Last close

$1.41 (as of 2026-10-16)

Market cap

$245,721,487

Average volume

3887801.0

Payment date

07/18/2019

Beta

1.62

Payout ratio

0.0%

P/E ratio

2.35

EPS

$0.60

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PALI risks and drawbacks

The deepest 1-year drawdown on record here is 51.8%.

Who may consider PALI — and who may not

It is a weaker fit for investors who need monthly cash flow (PALI does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on PALI

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions